帕金森病患者中 COVID-19 的患病率和结局：急症环境和医院。
Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital.
机构信息
Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital-UHN, Division of Neurology, University of Toronto, Toronto, ON, Canada.
Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital-UHN, Division of Neurology, University of Toronto, Toronto, ON, Canada; Krembil Research Institute, Toronto, ON, Canada; Center for Advancing Neurotechnological Innovation to Application (CRANIA), Toronto, ON, Canada.
出版信息
Int Rev Neurobiol. 2022;165:35-62. doi: 10.1016/bs.irn.2022.03.001. Epub 2022 Apr 20.
The global explosion of COVID-19 necessitated the rapid dissemination of information regarding SARS-CoV-2. Hence, COVID-19 prevalence and outcome data in Parkinson's disease patients were disseminated at a time when we only had part of the picture. In this chapter we firstly discuss the current literature on the prevalence of COVID-19 in people with PD. We then discuss outcomes from COVID-19 in people with PD, specifically risk of hospitalization and mortality. Finally, we discuss specific contributing and confounding factors which may put PD patients at higher or lower risk from COVID-19.
全球 COVID-19 的爆发需要快速传播有关 SARS-CoV-2 的信息。因此，当我们只了解部分情况时，就传播了帕金森病患者 COVID-19 的流行和结果数据。在本章中，我们首先讨论了当前关于 PD 患者 COVID-19 流行的文献。然后，我们讨论了 PD 患者 COVID-19 的结果，特别是住院和死亡的风险。最后，我们讨论了可能使 PD 患者面临更高或更低 COVID-19 风险的具体促成和混杂因素。
Zotero 插件